Opening remarks During the third quarter of the fiscal year, Hamlet Pharma has continued its clinical trial program for Alpha1H, a drug candidate in the…
Read More
Hamlet BioPharma the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections today launches the new website introducing…
The shareholders of Hamlet Pharma AB (publ) (“Hamlet Pharma” or the “Company”), reg. no. 556568-8958, are hereby invited to the extraordinary general meeting on Wednesday,…
The two pharmaceutical companies Hamlet Pharma AB and SelectImmune Pharma AB, listed on the Spotlight Stock Market, intend to merge and create a powerful pharmaceutical…
Hamlet Pharma, listed on Spotlight Stock Market, was awarded an EIC Accelerator grant of 2.2 M EURO in the highly competitive Horizon 2020 program. The…
An advertorial by Hamlet Pharma was published in The Guardian on December 6th. Entitled “Successful new drug candidate for patients with bladder cancer – from…
Colorectal cancer is a leading cause of death world-wide and more than 180,000 cases are diagnosed annually in the US alone. We now show that…
Hamlet Pharma develops new drug candidates to treat cancer without causing significant side effects. The drug candidate Alpha1H shows specificity for tumor tissue, where it…
MON, JUN 13, 2022 14:41 CETToday, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading expert…
Hamlet Pharma has participated in a number of recent events, presenting highligts from the promising clinical studies and our future strategy. With this newsletter, we…